Cogent Biosciences stock drops as analysts see tough competition for mastocytosis treatmentMarket Watch • 12/11/23
Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)GlobeNewsWire • 12/11/23
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)GlobeNewsWire • 12/09/23
Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer SymposiumGlobeNewsWire • 12/07/23
Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer SymposiumGlobeNewsWire • 11/29/23
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/02/23
Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 10/14/23
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/08/23
Does Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect?Zacks Investment Research • 07/11/23
Cogent Biosciences Announces Closing of Upsized Public Offering of Common StockGlobeNewsWire • 06/09/23
Cogent Biosciences Announces Participation in the Jefferies Healthcare ConferenceGlobeNewsWire • 06/07/23
Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST)GlobeNewsWire • 06/03/23
Cogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST)GlobeNewsWire • 05/23/23
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2023 Financial ResultsGlobeNewsWire • 05/09/23
Cogent Biosciences Presents Preclinical Data at AACR Annual Meeting Highlighting Precision Therapy Pipeline and Announces Initiation of Part 2 of the Registration-Enabling APEX Trial with Bezuclastinib in Advanced Systemic MastocytosisGlobeNewsWire • 04/17/23
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 03/14/23
Cogent Biosciences: Bezuclastinib's Potential In Treating Gastrointestinal Stromal TumorsSeeking Alpha • 02/28/23
Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer TherapeuticsGlobeNewsWire • 01/09/23
Cogent Biosciences Announces Presentation at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/05/23